Under terms of the deal, AbbVie will provide Neomorph with an upfront payment and the potential to earn up to $1.64 billion ...

Application is supported by results from the DEVOTE study, which suggested that two doses of Spinraza (nusinerse) 50 mg taken ...

As part of the regulatory action, memantine/donepezil extended-release capsules have been granted a 180-day exclusivity in ...

Trial findings show long-term recurrence-free survival in patients with low-grade upper tract urothelial cancer treated with ...

Arvinas, Inc, announced that its chief commercial officer, John Northcott, is stepping down as of mid-January. 1 While the ...

The trial, developed in collaboration with Novotech, will specifically target dietary and alcohol-induced overindulgence.

CIII nasal spray, marking the first monotherapy to be approved for adults with treatment-resistant depression (TRD).

The cobas liat test aims to improve patient outcomes by offering rapid, accurate results in decentralized and community-based ...

The two organizations will produce educational materials about the medicine and its importance for people living with type 1 ...

Panel participants share an optimistic outlook for integrating new innovations, tacking community-level challenges, and more.

Cary Claiborne, CEO, Adial Pharmaceuticals, discusses AD04’s development timeline and next steps towards approval for alcohol ...

PharmaScroll announced a new generative AI chatbot called Self-Serve AI. 1 The company describes it as a research and ...